Antibodies to Senescent Antigen and C3 Are Not Required for Normal Red Blood Cell Lifespan in a Murine Model

Krystalyn E. Hudson1,*, Karen de Wolski1, Linda M. Kapp1, Amanda L. Richards1, Matthew J. Schniederjan2 and James C. Zimring1,3,4

1Bloodworks Northwest Research Institute, Seattle, WA, United States, 2 Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States, 3Department of Laboratory Medicine, Division of Hematology, University of Washington, Seattle, WA, United States, 4 Department of Internal Medicine, Division of Hematology, University of Washington, Seattle, WA, United States

Red blood cells (RBCs) have a well-defined lifespan, indicating a mechanism by which senescent cells of a certain age are removed from circulation. However, the specifics by which senescent cells are recognized and removed are poorly understood. There are multiple competing hypotheses for this process, perhaps the most commonly cited is that senescent RBCs expose neoantigens [or senescent antigen(s)] that are then recognized by naturally occurring antibodies, which opsonize the senescent cells and result in clearance from circulation. While there are a large volume of published data to indicate that older RBCs accumulate increased levels of antibody on their surface, to the best of our knowledge, the causal role of such antibodies in clearance has not been rigorously assessed. In the current report, we demonstrate that RBC lifespan and clearance patterns are not altered in mice deficient in antibodies, in C3 protein, or missing both. These data demonstrate that neither antibody nor C3 is required for clearance of senescent RBCs, and questions if they are even involved, in a murine model of RBC lifespan.

Keywords: red blood cell clearance, complement C3, red blood cell lifespan, antibodies, senescent antigen, naturally occurring antibodies

INTRODUCTION

Red blood cells (RBCs) have a tightly regulated circulatory lifespan. The precise modifications that senescent RBCs undergo, which leads to their removal from circulation, remain incompletely understood. Previous studies in both humans and mice implicate similar pathways lead to senescent RBC clearance, including modulation of CD47 and phosphatidylserine expression, changes in density, and complement C3 deposition (1–8). However, among the most widely accepted explanations, is that age-related changes on the RBC surface expose neo-epitopes (broadly termed “senescent antigen”) that are recognized by naturally occurring antibodies, which then opsonize the senescent RBCs and lead to clearance. Indeed, Kay first reported that as RBCs age, more IgG is detectable on the RBC surface (9, 10), and multiple investigators have reproduced these findings over the past few decades. There have been several different hypotheses regarding the molecular basis for senescent antigen, including alteration and/or clustering of Band 3, alterations of surface carbohydrates and/or proteolysis of other proteins, and accumulation of oxidized and denatured proteins (11–17). Moreover, Lutz and colleagues reported that efficient phagocytosis of oxidized RBCs required C3b deposition in addition to Band 3 clustering and presence of anti-Band 3 autoantibodies (18, 19), suggesting a coordinated response between age-related changes in RBCs and the innate immune system. Thus,
the current model is that senescent antigen accumulates with RBC age, naturally occurring autoantibodies bind, prompt complement deposition and lead to subsequent clearance of older RBCs.

Despite the panoply of data and the multitude of papers that have been published on the role(s) of naturally occurring autoantibodies and complement in older RBC clearance through binding senescent antigen, to the best of our knowledge, the requirement of such autoantibodies has not been rigorously tested. The principal data claiming to demonstrate that senescent antigen-specific “Immunoglobulin (Ig) is required for phagocytosis” is based upon in vitro studies in which senescent RBCs are incubated with IgG followed by measurement of in vitro consumption by phagocytes (9). Additional data generated with reinfection of ex vivo biotin-labeled RBCs correlated accumulation of IgG with RBC removal (20). However, in addition to problems extrapolating from in vitro to in vivo biology, assessing whether RBC-labeling techniques inadvertently damage RBCs before reinfection, the previous studies can only assess whether an entity is capable of causing phagocytosis in vitro or is associated with clearance in vivo but lack the rigor to test whether it is required. Herein, we utilize transgenic mouse models with selective deletions in Ig and C3 genes to directly test the requirement of antibodies and complement in clearance of senescent RBCs. We report that neither Ig nor C3 are required for RBC clearance. Moreover, we demonstrate that erythropagocytosis by splenic leukocytes is not altered in the absence of antibodies or complement. Together, these findings demonstrate that neither antibodies nor complement C3 are required for clearance of senescent RBCs in a murine system.

In Vivo Erythropagocytosis

The assessment of cellular consumption of RBCs was carried out as previously described in methodological detail (25).

Statistical Analysis and Graphing

Statistical significance for three or more groups was evaluated by a one-way ANOVA followed by a Bonferroni’s posttest. Significance was set at $p \leq 0.05$ and $* \leq 0.05$, $** \leq 0.01$, $*** \leq 0.001$. Flow plots were generated using FlowJo software, and graphs were generated using GraphPad Prism.

RESULTS

To test the requirements of antibody and/or complement C3 for the clearance of RBCs as they senesce, the UBI-GFP transgene was bred onto Jh, C3KO, or JhxC3KO backgrounds. GFP+ RBCs were transfused into GFP− recipients, and lifespan of the RBCs was determined by enumerating GFP+ RBCs in recipient circulation over time by longitudinal analysis of individual animals, as described in Ref. (24). No significant difference was observed in RBC lifespan or clearance kinetics between wild-type B6, Jh, C3KO, or JhxC3KO mice (Figure 1). The use of GFP as an intracellular marker removes the requirement to label RBCs using dyes or tracers, and thus obviates concerns around damaging the RBCs during labeling and/or modifying surface antigens as a result of covalent attachment of label. This approach also eliminates concerns around introduction of C3 or Ig by donor mice, as donors and recipients both lack the same gene products. Moreover, given that each recipient received a syngeneic transfusion and RBC clearance was comparable between all strains (including control B6), these data demonstrate that the nature of the transgenic mouse did not affect RBC clearance pathways. In addition, these findings indicate that neither C3 nor Ig is required for senescent RBCs to be cleared at the end of their normal lifespan.

While the kinetics of RBC clearance was not significantly different in the absence of antibody and/or C3, this does not necessarily indicate similarities between strains in how the reticuloendothelial system removes senescent cells, as recognition and binding of naturally occurring antibodies and complement components may divert RBCs to specific leukocytes. To further investigate this issue, we analyzed the distribution of RBC consumption by leukocytes. The absence of B cells in Jh mice resulted in a significant decrease in overall numbers of splenocytes (Figure 2A). However, there was a significant fourfold increase in the percentage of red pulp macrophages (RPM), and also an increase (albeit less pronounced) in resident monocytes and neutrophils (Figure 2B). By contrast, there was no significant difference in percentages of different dendritic cell (DC) subsets, eosinophils, or inflammatory monocytes. C3KO had similar total splenocyte counts as B6 mice, with slight decreases in percentages of DC subsets and a small increase in RPM. Overall, the percentage of DiO+ leukocytes (white cells that had consumed RBCs) was highest in Jh mice, followed by C3KO, and lowest in B6 mice (Figure 2C). Measuring the MFI of a given populations as an indication of the amount of RBCs consumed per cell indicated that Jh mice had a significant increase in consumption by CD8− DCs and decreased consumption by RPM (Figure 2D). No other

MATERIALS AND METHODS

Mice

C57BL/6 (B6), UBI-GFP [C56BL/6-Tg(UBC-GFP)30Scha/J, stock #004353], Jh (B6.129P2-Igh-Jtm1Cgn/J, stock #002438), and C3KO (B6.129S4-C3tm1/Crr/J, stock #003641) were purchased from Jackson laboratories. UBI-GFP mice express green fluorescent protein (GFP) under the ubiquitin C promoter and have detectable GFP expression in every tissue examined (21). Jh mice lack Jh genes and are B cell deficient; as such, Jh mice have no detectable IgM or IgG (22). C3 null mice (C3KO) lack the complement component 3, which is essential for activation of the complement cascade and innate immune responses (23). All breeding was performed in the BloodworksNW vivarium. The UBI-GFP, Jh, and C3KO mice are each on a C57BL/6 background. Breeding was carried out to generate UBI-GFP heterozygotes on backgrounds of Jh, C3KO, or double knockout mice (JhxC3KO). All experiments were performed according to approved Institutional Animal Care and Use Committee (IACUC) procedures.

Kinetics and Duration of RBC Lifespan

Red blood cell lifespan was determined by enumerating donor RBCs by flow cytometry of GFP+ RBCs, as previously described (24). UBI-GFP RBCs were harvested from each of 4 UBI-GFP donor strains and 100 μL of packed RBCs were transfused into the corresponding recipient strain of the same genetic background, but GFP negative.
Untreated RBCs were used as a control, with no difference observed between wild-type and SCID mice, although little clearance was observed for untreated cells as the experimental observation was limited to 4 days. Rather than use these data to reject the hypothesis that antibodies were required, the authors interpreted these data as an indication that antibodies were indeed involved, but that there must be “an alternative pathway that is antibody-independent.” This conclusion seems to hinge on the observation that deletion of antibodies slightly delayed clearance by 1 day for neuraminidase treated cells (although the significance of this is unclear as no statistical analysis was provided). Although using “agammaglobulinemic mice” was a very reasonable approach, an additional problem is that the SCID mutation leaks on certain genetic backgrounds, including BALB/c, resulting in detectable serum Igs (27).

The current report uses Jh mice, which have a deletion of an essential part of the Ig gene, decreasing (if not eliminating) the risk of leakiness. We observed no difference in RBC lifespan in agam- maglobulinemic mice vs. wild-type controls. Likewise, we observed no difference in RBC lifespan in C3KO mice. C3b, a product of C3, has been argued to be essential to antibody-mediated clearance of senescent RBCs (18, 28, 29). C3 has also been argued to be capable of mediating RBC clearance in the absence of antibody, at least in the context of clearance of stored RBCs (30, 31). If Igs or C3 were required for RBC clearance, then the removal of either (or both) would be predicted to result in a longer RBC circulatory lifespan; such was not observed. While it is not logically feasible to exclude the possibility of any redundant pathway, the normal RBC lifespan in the indicated strains would require the supposition of a third pathway to rescue the hypothesis, one that maintained the same pattern of clearance by reticuloendothelial cells. This is not to imply, in any way, that a very strong association does not exist between aging RBCs and surface Ig and/or C3; such observations have been made by multiple investigators over decades, and are not in dispute. However, the current data do undermine the notion that association is a causal relationship and provide evidence that neither surface Igs nor C3 (or both) are required for clearance of senescent RBCs. Finally, we cannot rule out that compensatory RBC clearance mechanisms evolved due to an absence of antibodies, complement C3, or both in response to their genetic modifications. However, we think this is unlikely due to the similarity of RBC clearance and consumption patterns in the different transgenic mice compared with controls.

Many hypotheses have been put forth to explain the mechanism(s) of clearance of senescent RBCs but much controversy remains. Much work has been done on human RBCs, giving rise to correlations (e.g., increased Ig on RBCs over time). However, causality can only be specifically tested by removing a variable and observing its effect. Typically, this is neither logistically nor ethically feasible in humans, and is a limitation of experimentation on human systems. The plethora of genetically modified mice allow for removal of a specific potential maker (or mechanism) of senescent RBCs with relative ease. In addition, human studies have not been able to directly test this hypothesis in vivo in a causal way, and has had to use in vitro modeling. For example, much of the human data have had to resort to using density centrifugation to separate “young” and “old” RBCs to identify markers of senescence, and recent data have demonstrated that these cell populations are not pure. Alternatively, much human

statistically significant differences were observed; no differences were detected between C3 and B6 mice.

**DISCUSSION**

In aggregate, these data demonstrate that in the absence of antibodies, C3, or both simultaneously, circulatory lifespan of RBCs is not altered. While the amount of RBCs consumed by any particular macrophage is slightly lower in Jh mice, this is offset by the increased number of macrophages present, such that overall consumption is not altered. Together, the findings in this paper bring into serious question the hypothesis that normal RBC senescence is mediated by Igs and/or requires complement C3.

This manuscript is, to the best of our knowledge, the first paper to demonstrate that clearance of senescent RBCs can occur without antibodies, C3, or both. This conclusion seems to hinge on the observation that deletion of antibodies slightly delayed clearance by 1 day for neuraminidase treated cells (although the significance of this is unclear as no statistical analysis was provided). Although using “agammaglobulinemic mice” was a very reasonable approach, an additional problem is that the SCID mutation leaks on certain genetic backgrounds, including BALB/c, resulting in detectable serum Igs (27).

The current report uses Jh mice, which have a deletion of an essential part of the Ig gene, decreasing (if not eliminating) the risk of leakiness. We observed no difference in RBC lifespan in agammaglobulinemic mice vs. wild-type controls. Likewise, we observed no difference in RBC lifespan in C3KO mice. C3b, a product of C3, has been argued to be essential to antibody-mediated clearance of senescent RBCs (18, 28, 29). C3 has also been argued to be capable of mediating RBC clearance in the absence of antibody, at least in the context of clearance of stored RBCs (30, 31). If Igs or C3 were required for RBC clearance, then the removal of either (or both) would be predicted to result in a longer RBC circulatory lifespan; such was not observed. While it is not logically feasible to exclude the possibility of any redundant pathway, the normal RBC lifespan in the indicated strains would require the supposition of a third pathway to rescue the hypothesis, one that maintained the same pattern of clearance by reticuloendothelial cells. This is not to imply, in any way, that a very strong association does not exist between aging RBCs and surface Ig and/or C3; such observations have been made by multiple investigators over decades, and are not in dispute. However, the current data do undermine the notion that association is a causal relationship and provide evidence that neither surface Igs nor C3 (or both) are required for clearance of senescent RBCs. Finally, we cannot rule out that compensatory RBC clearance mechanisms evolved due to an absence of antibodies, complement C3, or both in response to their genetic modifications. However, we think this is unlikely due to the similarity of RBC clearance and consumption patterns in the different transgenic mice compared with controls.

Many hypotheses have been put forth to explain the mechanism(s) of clearance of senescent RBCs but much controversy remains. Much work has been done on human RBCs, giving rise to correlations (e.g., increased Ig on RBCs over time). However, causality can only be specifically tested by removing a variable and observing its effect. Typically, this is neither logistically nor ethically feasible in humans, and is a limitation of experimentation on human systems. The plethora of genetically modified mice allow for removal of a specific potential maker (or mechanism) of senescent RBCs with relative ease. In addition, human studies have not been able to directly test this hypothesis in vivo in a causal way, and has had to use in vitro modeling. For example, much of the human data have had to resort to using density centrifugation to separate “young” and “old” RBCs to identify markers of senescence, and recent data have demonstrated that these cell populations are not pure. Alternatively, much human
data have used heat or chemically damaged RBCs to model aging, and it is unclear that such models reflect the natural aging process. Moreover, the murine model provides a powerful platform, such as the exploitation of GFP+ mice, that avoids the need for excessive ex vivo manipulations (e.g., biotinylation) before reinfusion. As such, animal modeling provides an opportunity to test causality; but in doing so, raises the possibility that the biology of the animal may not reflect that of humans. Mice are not humans, and as such, the data herein may not reflect human biology. That having been said, murine and human RBC biology lines up in many ways, most importantly to the current studies, that Ig accumulates on RBCs as they age in both species. As such, the current studies provide new evidence arguing against an essential role of Ig or C3 for RBC clearance in mice, and suggest the same may be true in humans. Should a way to ethically test this directly in humans and in vivo be devised, then extending the direct scrutiny of this hypotheses in humans will be an important next step.

ETHICS STATEMENT

All procedures were performed according to approved BloodworksNW Institutional Animal Care and Use Committee (IACUC) protocols.

AUTHOR CONTRIBUTIONS

KH, Kd, LK, AR, MS, and JZ each performed experiments and analyzed data contained in this work. KH and JZ authored the manuscript and Kd, LK, AR, and MS provided revisions. All the authors read and approved of the manuscript.
ACKNOWLEDGMENTS

The authors would like to thank Dr. Steven Spitalnik for his intellectual input and encouragement regarding these studies.

REFERENCES

1. Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, Van Bruggen R. CD47 functions as a molecular switch for erythocyte phagocytosis. Blood (2012) 119:5512. doi:10.1182/blood-2011-10-386805
2. Khandelwal S, Van Rooijen N, Saxena R. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion (2007) 47:1725–32. doi:10.1111/j.1537-2995.2007.01348.x
3. Lang F, Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif (2012) 33:125–30. doi:10.1159/000334163
4. Boas FE, Forman L, Beutler E. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc Natl Acad Sci U S A (1998) 95:3077–81. doi:10.1073/pnas.95.6.3077
5. Schrott AJ, Madsen JW, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem (1985) 260:5311–8.
6. Kay M, Bosman G, Johnson G, Beth A. Band-3 polymers and aggregates, and hemoglobin precipitates in red cell aging. Blood Cells (1988) 14:275–95.
7. Kay MM, Goodman SR, Sorensen K, Whitfield CF, Wong P, Zaki L, et al. Senescent cell antigen is immunologically related to band 3. Proc Natl Acad Sci U S A (1983) 80:1631–5. doi:10.1073/pnas.80.22.6882
8. Bogdanova A, Lutz H. Mechanisms tagging senescent red blood cells for clearance in healthy humans. Front Physiol (2013) 4:387. doi:10.3389/fphys.2013.00387
9. Kay MM. Mechanism of removal of senescent cells by human macrophages in situ. Proc Natl Acad Sci U S A (1975) 72:3521–5. doi:10.1073/pnas.72.9.3521
10. Kay MM. Isolation of the phagocytosis-inducing IgG-binding antigen on senescent somatic cells. Nature (1981) 5:491–5. doi:10.1038/289491a0
11. Bratosin D, Mazurier J, Tissier JP, Estiquier J, Huart JJ, Ameisen JC, et al. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie (1998) 80:173–95. doi:10.1016/S0300-9084(98)80024-2
12. Clark MR. Senescence of red blood cells: progress and problems. Physiol Rev (1988) 68:503.
13. Kiefer C, Snyder L. Oxidation and erythrocyte senescence. Curr Opin Hematol (2000) 7:113–6. doi:10.1097/00062752-200003000-00007
14. Antonelou MH, Kriebarsid AG, Papassideri IS. Aging and death signalling in mature red cells: from basic science to transfusion practice. Blood Transfus (2010) 8:39–47. doi:10.2450/2010.0007S
15. Antonelou MH, Kriebarsid AG, Stamosulis KE, Troupakos JP, Papassideri IS. Apolipoprotein J/Clusterin is a novel structural component of human erythrocytes and a biomarker of cellular stress and senescence. PLoS One (2011) 6: e26032. doi:10.1371/journal.pone.0026032
16. D’Alessandro A, Blasi B, D’Amici GM, Marrocco C, Zolla L. Red blood cell subpopulations in freshly drawn blood: application of proteomics and metabolomics to a decades-long biological issue. Blood Transfus (2013) 11:75–87. doi:10.2450/2012.0164-11
17. Xu X, von Löhniesen K, Soldau K, Noack D, Vu A, Friedman JS. A novel approach for in vivo measurement of mouse red cell redox status. Blood (2011) 118:3694. doi:10.1182/blood-2011-03-342113
18. Lutz HU. Naturally occurring autoantibodies in mediating clearance of senescent red blood cells. In: Lutz H, editor. Naturally Occurring Antibodies (NAbs). (Vol. 750). New York: Springer (2012). p. 76–90.
19. Lutz HU, Stammler P, Fasler S. Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. J Biol Chem (1993) 268:17418–26.
20. Franco RS, Puchulhu-Campanella ME, Barter LA, Palacsek MB, Joiner CH, Low PS, et al. Changes in the properties of normal human red blood cells during in vivo aging. Am J Hematol (2013) 88:44–51. doi:10.1002/ajh.23344
21. Schaefer BC, Schaefer ML, Kappler Jw, Marrack P, Kedl RM. Observation of antigen-dependent CD8+ T-cell/dendritic cell interactions in vivo. Cell Immunol (2001) 214:110–22. doi:10.1006/cimm.2001.1895
22. Gu H, Zou YR, Rajewsky K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell (1993) 73:1155–64. doi:10.1016/0092-8674(93)90644-6
23. Wessels MR, Butko P, MaM, Warren HR, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A (1995) 92:11490–4. doi:10.1073/pnas.92.25.11490
24. Wilson CR, Kraus T, Hod EA, Hendrickson J, Spitalnik SL, Hillyer CD, et al. A novel mouse model of red blood cell storage and post-transfusion in vivo survival. Transfusion (2009) 49:1546–53. doi:10.1111/j.1537-2995.2009.02173.x
25. Richards AL, Hendrickson JE, Zimring JC, Hudson KE. Erythropagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation. Transfusion (2016) 56:905–16. doi:10.1111/trf.13497
26. Bratosin D, Estaquier J, Ameisen JC, Aminoff D, Montreuil J. Flow cytometric approach to the study of erythropagocytosis: evidence for an alternative immunoglobulin-independent pathway in agammaglobulinemic mice. J Immunol Methods (2002) 265:133–43. doi:10.1016/S0022-1759(02)00076-5
27. Nonoyama S, Smith FO, Bernstein ID, Ochs HD. Strain-dependent leukocytosis of mice with severe combined immune deficiency. J Immunol (1993) 150:3817.
28. Lutz HU, Fasler S, Stammler P, Bussolino F, Arese P. Naturally occurring anti-band 3 antibodies and complement in phagocytosis of oxidatively-stressed and in clearance of senescent red cells. Blood Cells (1988) 14:173–203.
29. Lutz HU, Bussolino F, Flepp R, Fasler S, Stammler P, Kazatchkine MD, et al. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 84:7368–72. doi:10.1073/pnas.84.21.7368
30. Szymanski IO, Odgren PR. Studies on the preservation of red blood cells. Vox Sang (1979) 36:213–24. doi:10.1111/j.1423-0410.1979.tb04427.x
31. Szymanski IO, Odgren PR, Valeri CR. Relationship between the third component of human complement (C3) bound to stored preserved erythrocytes and their viability in vivo. Vox Sang (1985) 49:34–41. doi:10.1111/j.1423-0410.1985.tb00765.x

FUNDING

This work was supported, in part, by the National Blood Foundation and discretionary funding from BloodworksNW.

Conflict of Interest Statement: KH, KD, IK, AR, and MS have no conflicts of interest to declare. IZ serves on the Scientific Advisory Board for Rubius Therapeutics and consults or Surface Oncology and Sinopia Biosciences.

Copyright © 2017 Hudson, de Wolski, Kapp, Richards, Schmiederjan and Zimring. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.